Girish Bathla MBBS, Presenter: Nothing to Disclose

Bruno A. Policeni MD, Abstract Co-Author: Nothing to Disclose

Toshio Moritani MD, PhD, Abstract Co-Author: Nothing to Disclose

Aristides Andres Capizzano MD, Abstract Co-Author: Nothing to Disclose

Manish Bajaj MBBS, MD, Abstract Co-Author: Nothing to Disclose

1) To discuss the spectrum of imaging findings in both primary and secondary CNS lymphoma and revisit useful imaging signs. 2) To briefly review imaging of treatment related neurotoxicity and other CNS complications.  

Primary CNS lymphoma [PCNSL] accounts for 1-5% of primary brain neoplasms. Given the increasing incidence, it is projected to become the most common primary brain neoplasm over the next decade. PCNSL can have a myriad of appearances although the location, appearance and epidemiology vary between immunocompetent and immunocompromised patients. It may present as a parenchymal, ventricular or meningeal lesion or uncommonly, may mimic infarcts or diffuse parenchymal infiltration. Lymphomatous CNS involvement may also occur in systemic disease, either at initial presentation or during relapse. In the later instance, CNS involvement may antedate or accompany systemic relapse. Treatment related neurotoxicity may occur due to chemo/ radiation therapy and frequently manifests as diffuse or focal white matter changes, volume loss or shunt infection. Understanding of the underlying disease, its imaging and complications are of vital importance to the radiologist to avoid misdiagnosis and potential pitfalls.  

http://abstract.rsna.org/uploads/2014/14003480/14003480_4gjz.pdf

Bathla, G, Policeni, B, Moritani, T, Capizzano, A, Bajaj, M, Imaging Of CNS Lymphoma and Its Treatment Complications: Typical, Atypical and Bizarre!.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14003480.html